Open AccessEffectiveness of D-Rd program in the first line therapy of a 75-year-old female patient with multiple myeloma with high-risk cytogenetics. Clinical observation
Author(s) -
Yu. E. Ryabukhina,
F. M. Abbasbeyli,
P. A. Zeynalovа,
О. Л. Тимофеева,
Н. А. Купрышина,
А. Г. Жуков
Publication year - 2022
Publication title -
md-onco
Language(s) - English
Resource type - Journals
eISSN - 2782-6171
pISSN - 2782-3202
DOI - 10.17650/2782-3202-2022-2-3-28-35
Subject(s) - multiple myeloma , cytogenetics , minimal residual disease , medicine , oncology , bone marrow , daratumumab , plasma cell , immunology , biology , bortezomib , genetics , chromosome , gene